A 7 year follow-up prospective cohort study identified the function of an SREBP2 polymorphism (rs133291) in non-obese NAFLD and its association with a higher OR for NASH (odds ratio = 2.92, 95% CI = 2.08–4.18, p = 0.002) [50]. Here, SREBF2 is linked to metabolic dysfunction-associated steatotic liver disease.